Acetylator polymorphism in Alzheimer's disease.
To elucidate whether any relationship exists between genetic acetylator polymorphism and the risk of developing Alzheimer's disease. Acetylator polymorphism has been determined, using sulphamethazine, in 54 patients with Alzheimer's disease or senile dementia of Alzheimer type and in 93 age-matched controls. Thirty-one patients (57.4%) and 54 controls (58%) were classified as slow acetylators (non-significant difference). No relation was found between acetylator polymorphism and age at onset of disease and scores of Minimental examination and Blessed, Tomlinson & Roth scale in the group of patients with Alzheimer's disease/senile dementia of Alzheimer type. Our results do not support the existence of any relationship between acetylator polymorphism and the risk of developing Alzheimer type dementia.